| | | hhs statement about binaxnow:
hhs.gov
fda august statement:
fda.gov
atlantic october article:
theatlantic.com
“...The point I'm trying to make here, and I'll be blunt, is that antigen testing will not and cannot work for asymptomatic screening, and [it] will probably kill a lot of people,” Geoffrey Baird, the acting laboratory-medicine chair at the University of Washington, told us...
The [FDA] emergency use authorization only covered testing for people within the first seven days of developing symptoms, when viral loads remain high.
...in the general, symptom-free population, the expected levels of infection are actually quite low, so the false-positive rate could be very high.
...“One branch of the government is saying, ‘Use this test for asymptomatic people,’ and then on the other side, they are saying, ‘Use this test for symptomatic people,’” he said. Baird is particularly anxious that the performance of tests will deteriorate in the field and when applied to asymptomatic people.
|
|
